• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Florbetaben (18F)     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatRadiopharmaceuticals, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substancePill (pharmacy)yago:WikicatMolecularFormulasyago:Abstraction100002137yago:Agent114778436yago:CausalAgent100007347yago:Communication100033020yago:Drug103247620yago:Formula106816935yago:Matter100020827yago:Medicine103740161yago:Message106598915yago:MolecularFormula106817173yago:Pharmaceutical103920989yago:PhysicalEntity100001930yago:Radiopharmaceutical104043268drugyago:Statement106722453yago:Substance100020090yago:WikicatRadiopharmaceuticals New Facet based on Instances of this Class

Florbetaben, a fluorine-18 (18F)-labeled stilbene derivative (formerly known as BAY-949172), trade name NeuraCeq, is a diagnostic radiotracer developed for routine clinical application to visualize β-amyloid plaques in the brain. It is indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. β-amyloid is a key neuropathological hallmark of AD, so markers of β-amyloid plaque accumulation in the brain are useful in distinguishing AD from other causes of dementia. The tracer successfully completed a global multicenter phase 0–III development program and obtained approval in Europe, US and South Korea in 20